NPHC NUTRA PHARMA ORD revenue, earnings and financials
For the quarter ended June 30, 2026, NUTRA PHARMA ORD reported revenue of $34.5K (down 59.2% from a year earlier), net income of −$3.95M and diluted EPS of $0.00; over the last four quarters revenue was $161K and net income −$5.42M; for the fiscal year ended December 2025 revenue was $258K, up 4.6% on the year before.
NPHC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $258K, gross profit $197K, operating income −$1.46M, net income −$2.05M (margin -794.8%), EPS $0.00
- Fiscal year ended Dec 2024: revenue $246K, gross profit $247K, operating income −$878K, net income −$1.29M (margin -522.0%), EPS $0.00
- Fiscal year ended Dec 2023: revenue $206K, gross profit $396K, operating income −$887K, net income −$1.39M (margin -677.8%), EPS $0.00
- Fiscal year ended Dec 2022: revenue $146K, gross profit $249K, operating income −$1.91M, net income $8.18M (margin 5608.3%), EPS $0.00
- Fiscal year ended Dec 2021: revenue $97.7K, gross profit $8.47K, operating income −$1.99M, net income −$13.1M (margin -13399.0%), EPS −$0.00
NPHC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $34.5K (down 59.2% year over year), net income −$3.95M, EPS $0.00
- Quarter ended Mar 31, 2026: revenue $27.2K (down 63.2% year over year), net income −$460K, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue $28.9K (down 64.7% year over year), net income −$489K, EPS $0.00
- Quarter ended Sep 30, 2025: revenue $70.2K (down 6.3% year over year), net income −$524K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue $84.5K (up 63.5% year over year), net income $370K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue $74.0K (up 96.1% year over year), net income −$1.40M, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue $81.9K (up 74.1% year over year), net income −$231K, EPS $0.00
- Quarter ended Sep 30, 2024: revenue $75.0K (up 45.3% year over year), net income −$261K, EPS $0.00
- Quarter ended Jun 30, 2024: revenue $51.7K (down 1.3% year over year), net income −$367K, EPS $0.00
- Quarter ended Mar 31, 2024: revenue $37.7K (down 30.8% year over year), net income −$427K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue $47.0K (down 40.5% year over year), net income −$243K, EPS $0.00
- Quarter ended Sep 30, 2023: revenue $51.6K (up 109.6% year over year), net income −$278K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue $52.4K (up 84.3% year over year), net income −$279K, EPS $0.00
- Quarter ended Mar 31, 2023: revenue $54.5K (up 296.3% year over year), net income −$593K, EPS $0.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue $79.0K (up 203.9% year over year), net income $3.23M, EPS $0.00
- Quarter ended Sep 30, 2022: revenue $24.6K (up 27.8% year over year), net income $577K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue $28.4K (down 6.7% year over year), net income −$646K, EPS $0.00
- Quarter ended Mar 31, 2022: revenue $13.8K (down 37.5% year over year), net income $5.01M, EPS $0.00
- Quarter ended Dec 31, 2021 (from the annual report): revenue $26.0K, net income $2.13M, EPS −$0.00
- Quarter ended Sep 30, 2021: revenue $19.3K, net income $15.4M, EPS $0.00
NPHC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.16M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$424K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$550K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$762K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.74M, share buybacks n/a
NPHC balance sheet
- Jun 30, 2026: cash n/a, total assets $623K, total liabilities $21.8M, shareholders' equity −$21.2M, long-term debt $135K
- Mar 31, 2026: cash n/a, total assets $617K, total liabilities $17.9M, shareholders' equity −$17.3M, long-term debt $136K
- Dec 31, 2025: cash $12.2K, total assets $623K, total liabilities $17.4M, shareholders' equity −$16.8M, long-term debt $137K
- Sep 30, 2025: cash n/a, total assets $710K, total liabilities $17.1M, shareholders' equity −$16.4M, long-term debt $138K
- Jun 30, 2025: cash n/a, total assets $859K, total liabilities $16.7M, shareholders' equity −$15.8M, long-term debt $138K
- Mar 31, 2025: cash n/a, total assets $775K, total liabilities $17.0M, shareholders' equity −$16.2M, long-term debt $139K
- Dec 31, 2024: cash $36.4K, total assets $599K, total liabilities $15.4M, shareholders' equity −$14.8M, long-term debt $140K
- Sep 30, 2024: cash $0, total assets $559K, total liabilities $15.4M, shareholders' equity −$14.8M, long-term debt $141K
What is NPHC's revenue?
NUTRA PHARMA ORD reported $161K of revenue over its last four quarters, through June 30, 2026.
Is NPHC profitable?
No. NUTRA PHARMA ORD lost $5.42M over the last four quarters.
What is NPHC's EPS?
Diluted earnings per share over the last four quarters were $0.00; $0.00 in the latest quarter.